خبر جديد وساخن على caly

[ممدوح]

Calypte Receives Exemption from FDA Lot Release Testing
جديد وحار
http://biz.yahoo.com/bw/030108/80028_1.html

اطنه خبر زين
وينك يا بو حمد ما تسمع الكلام

[sa41sa41]

اليو رايح توصل ممكن 0.09$
هذا الخبر الثانى خللال 6-7/1/2002
عن المنتج الذى سوف يسوق تجريبى
سلمت لصين الدفعة الاولى

[sa41sa41]

تصحيح 6-7/1/2003

[streamer]

اخواني اعتقد الخبر جيد جدا حيث اعفت منظمة الادوية والاغذية شركة كالي من اختبارات وبحوث كانت يفترض علي الشركة ان تجريها .. وهذا يعني ان المنظمة باعفائها عن البنود هذه تثق بنتائج الشركة وتختصر عليها اجرائات طويلة وذلك سوف يساعد الشركة علي البدء في عمليات التسويق خلال فترة اسبوعين من الان ..

اعتقد اخواني ان السهم سوف يحلق اكثر من ذلك بكثير جدا ما هو رايك اخي ممدوح؟

[streamer]

هل تبيع مع ارتفاع اليوم او هناك فرصة لسهم للتحليق خلال الايام القليلة القادمة وقد يصل الي 40 سنت ؟؟

اسهم البيني لا احد يستطيع التنبا بها ؟؟

افيدونا اخواني

[ممدوح]

انا استطيع الجزم ان سعر 0.12 مضمون
وسعر 0.16 هو الذي وضعت عليه امر البيع
وسعر 0.40 لا يستبعد بأي حال من الاحوال
والطمع شين
ههههههههههههههههه

[streamer]

والله صاج يا ممدوج الطمع شين بس اهي امنيات الواحد يتمنا انها تتحقق والشركة يا اخي امرها عجيب لانها شركة ذات منتج مميز وقوي ووحيد من نوعة ولمفروض تعمل ثورة في عالم الكشف عن المرض والعياذ بالله ..

الا ان الادارة اعتقد موش ول ابد وعملية التسويق فاترة نوعا ما ..

ومثل ما اتفضلت الطمع ماهو بزين وانشالله نقتدي بتوصياتك .. والتوفيق للجميع

الاخ ابو بني الغائب الحاضر كان راح يفرح بالخبر هذا ..

الله الموفق

[سيف الخيال]

قبل 8 شهور تقريبا هذا السهم اقلع من 0.01 سنت الى 0.43 سنت .

ولا استبعد ان يعملها ، خصوصا وان هذا القطاع ، قطاع مجنون ....

واشترينا 50000 سهم ونبي ننساها عسى ان يقلع ويعمل الحركة التي عملها سابقا هههههه

وان ما سواها نطمح بالبيع على 0.12 سنت ان شاء الله .

والله يكثر الاخبار الطيبة ان شاء الله .......

[streamer]

واتقولي لا تطمع يا ممدوح ههههههههههه

موفق يا الحازمي انشالله وممدوح والجميع انشالله

[محترف]

الاخوان اللة يبشركم بالخير على هذة الاخبار الزينة وظن وللة اعلم ان ال 40و شوية فى حقها ولكن

المصيبة في هذا الدلخ بوش لن ينتعش الاقيصاد وهو فى الحكم نتمنى من اللة ان يزيلة

تحياتى للجميع

[sa41sa41]

شريت 70000 الف ووضعت البيع 0.16 سنت ومتى موصل خير وبركة
مانى احسن من الاخ ممدوح

[streamer]

يوجد اقبال علي الشراء .. انشالله نستبشر خيرا قريبا

موفقين اجمعين

http://iw.thomsonfn.com/iwatch/cgi-bin/iw_ticker?ticker=caly&symbol=caly

[streamer]

J. Richard George, CDC and HIV Veteran Joins Calypte as VP of Government Affairs

ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 10, 2003--

HIV and Infectious Diseases Expert Now Responsible for Calypte's

Expanding Global Government Relations Programs

Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, today announced that Dr. Richard George has joined Calypte as Vice President of Government Affairs. In this newly created position, Dr. George will be responsible for working with a variety of public sector and government-sponsored agencies around the world to increase awareness of the importance of HIV testing, highlight the benefits of urine-based testing, develop HIV testing programs and secure capital to fund programs.

Prior to joining Calypte, Dr. George worked for OraSure Technologies, Inc. (Nasdaq:OSUR) as Senior Vice President of Research and Development for infectious diseases. During his tenure at OraSure, he supervised the successful development of the recently FDA-approved OraQuick Rapid HIV-1 blood test, including product development, product support, and clinical trials. Previously, he was Chief Scientific Officer for Epitope, Inc., now OraSure, where he was responsible for all scientific programs relating to new products including those focused on testing for HIV/AIDS.

Prior to joining Epitope, Dr. George spent 34 years at the U.S. Centers for Disease Control and Prevention (CDC) in positions of increasing responsibility, most recently serving as the Chief of Developmental Technology Section in the AIDS Program where he provided laboratory support and coordination for the CDC's international HIV/AIDS projects. These projects included maintaining global surveillance of emerging strains of HIV, conducting tests on genetic variations of HIV, and developing new antibody-based methods for identifying HIV strains. Dr. George used the results of his efforts to collaborate with such entities as the World Health Organization (WHO), and the Pan American Health Organization (PAHO), to strive for standardized HIV testing in developing countries.

"We are thrilled to have a professional of Richard's caliber join Calypte, and his scientific and global government relations expertise will prove invaluable to our team," stated Nancy Katz, president and CEO of Calypte. "We look forward to significant progress in securing relationships with several influential organizations to demonstrate the merits of our urine-based HIV tests. His career and core competency in HIV at the CDC and at OraSure will propel a dynamic synergy in advancing relations between Calypte, government agencies and global health organizations."

Dr. George is a past and present member of several scientific societies such as the American Society of Microbiology and continues to be a consultant to the WHO and the University of Pennsylvania. He has won numerous awards for scientific excellence throughout his career, has more than 100 scientific publications to his credit and has served as a Scientific Reviewer for the international journal AIDS and the Journal of Medical Virology.

About Calypte

Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Refer to current product package inserts for complete information on product performance characteristics. More information about Calypte can be found at www.calypte.com.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue and expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K/A (No.1) for the year ended December 31, 2001 and its subsequent filings with the SEC.

--30--am/sf*

CONTACT: Calypte Biomedical Corporation
Nancy Katz, 510/749-5100
nkatz@calypte.com
or
Lippert/Heilshorn & Associates
Brendan Lahiff/Kirsten Chapman, 415/433-3777
brendan@lhai-sf.com

[الملك الصغير]

ولكن رأيي المتواضع يقول....... السهم هذا حاليا مكون تركيبة بيريش....يعني هبوط ......ثلاث شمعات ...مع الهاي الأوسط أعلى من الارتفاعين المحيطين فيه......إذا احتمال كبير السهم يهبط في الفترة القادمة:).........انتظر إشارة الشراء القادمة.......وأتمنى أكون مخطئ:)

الملك الصغير اللي راح يكبر بمساعدتكم:)

[streamer]

اخي الملك الصغير هل تعتقد ان اسهم البيني ستوك تقع تحت تاثير قوي من ناحية التحليل الفني ؟ بالمقارنة مع اي خبر جيد او اخبار متتابعة يمكنها ان تغير مجري حركة السهم بشكل سريع ؟

الله الموفق

[streamer]

اخواني قرات مشاركة في احد المنتدايات خبر يفيد بنية الشركة لزيادة عدد الاسهم المطروحة .. ما هو تاثير هذا الخبر وهل هي نية لعمل تقسيم عكسي للسهم؟

PROXY: Calypte to Vote to Increase AUTH Shares

THURSDAY , JANUARY 09, 2003 03:47 PM

Calypte Biomedical Corporation (OTCBB: CALY) filed a PRE 14A during Thursday’s session to announce that the Company will hold a Special Meeting of Stockholders on Friday, February 14, 2003 at 8:00 a.m. PST in Alameda, CA to consider and vote to increase the number of authorized shares of the Company’s Common Stock from 200,000,000 to 800,000,000.

[ممدوح]

امس قبل نهاية السوق بساعة شاهدت على السهم شراء بالبلوكات 100 الف وخمسن الف وهكذا
وكتبت في نفس الموضوع في وقتها اكيد فيه خبر على السهم ولسوء الحظ لم يكتمل ردي لسوء الاتصال وكنت فاتح نوافذ كثيرة
اليوم فيه خبر على السهم
وعلى الاخ الذي شرى 70 الف سهم ان يبيع بالمكسب ويتابع السهم ويتحين فرصة البيع والرزق على الله
اما انا فقد بعت يوم امس على 0.071
والرزق على الرب الكريم
J. Richard George, CDC and HIV Veteran Joins Calypte as VP of Government Affairs
10 Jan 2003, 07:00am ET
E-mail or Print this story
- - - - -

ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 10, 2003--

HIV and Infectious Diseases Expert Now Responsible for Calypte's
Expanding Global Government Relations Programs

Calypte Biomedical Corporation (OTCBB:CALY), the developer and
marketer of the only two FDA-approved HIV-1 antibody tests that can be
used on urine samples, as well as an FDA-approved serum HIV-1 antibody
Western Blot supplemental test, today announced that Dr. Richard
George has joined Calypte as Vice President of Government Affairs. In
this newly created position, Dr. George will be responsible for
working with a variety of public sector and government-sponsored
agencies around the world to increase awareness of the importance of
HIV testing, highlight the benefits of urine-based testing, develop
HIV testing programs and secure capital to fund programs.
Prior to joining Calypte, Dr. George worked for OraSure
Technologies, Inc. (Nasdaq:OSUR) as Senior Vice President of Research
and Development for infectious diseases. During his tenure at OraSure,
he supervised the successful development of the recently FDA-approved
OraQuick Rapid HIV-1 blood test, including product development,
product support, and clinical trials. Previously, he was Chief
Scientific Officer for Epitope, Inc., now OraSure, where he was
responsible for all scientific programs relating to new products
including those focused on testing for HIV/AIDS.
Prior to joining Epitope, Dr. George spent 34 years at the U.S.
Centers for Disease Control and Prevention (CDC) in positions of
increasing responsibility, most recently serving as the Chief of
Developmental Technology Section in the AIDS Program where he provided
laboratory support and coordination for the CDC's international
HIV/AIDS projects. These projects included maintaining global
surveillance of emerging strains of HIV, conducting tests on genetic
variations of HIV, and developing new antibody-based methods for
identifying HIV strains. Dr. George used the results of his efforts to
collaborate with such entities as the World Health Organization (WHO),
and the Pan American Health Organization (PAHO), to strive for
standardized HIV testing in developing countries.
"We are thrilled to have a professional of Richard's caliber join
Calypte, and his scientific and global government relations expertise
will prove invaluable to our team," stated Nancy Katz, president and
CEO of Calypte. "We look forward to significant progress in securing
relationships with several influential organizations to demonstrate
the merits of our urine-based HIV tests. His career and core
competency in HIV at the CDC and at OraSure will propel a dynamic
synergy in advancing relations between Calypte, government agencies
and global health organizations."
Dr. George is a past and present member of several scientific
societies such as the American Society of Microbiology and continues
to be a consultant to the WHO and the University of Pennsylvania. He
has won numerous awards for scientific excellence throughout his
career, has more than 100 scientific publications to his credit and
has served as a Scientific Reviewer for the international journal AIDS
and the Journal of Medical Virology.

About Calypte

Calypte Biomedical Corporation, headquartered in Alameda,
California, is a public healthcare company dedicated to the
development and commercialization of urine-based diagnostic products
and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually
transmitted diseases and other infectious diseases. Calypte's tests
include the screening EIA and supplemental Western Blot tests, the
only two FDA-approved HIV-1 antibody tests that can be used on urine
samples, as well as an FDA-approved serum HIV-1 antibody Western Blot
test. The company believes that accurate, non-invasive urine-based
testing methods for HIV and other infectious diseases may make
important contributions to public health by helping to foster an
environment in which testing may be done safely, economically, and
painlessly. Calypte markets its products in countries worldwide
through international distributors and strategic partners. Refer to
current product package inserts for complete information on product
performance characteristics. More information about Calypte can be
found at www.calypte.com.

Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of
1933, as amended. Those statements include statements regarding the
intent, belief or current expectations of the Company and its
management. Such statements reflect management's current views, are
based on certain assumptions and involve risks and uncertainties.
Actual results, events, or performance may differ materially from the
above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not
limited to, our ability to obtain additional financing and access
funds from our existing financing arrangements that will allow us to
continue our current and future operations and whether demand for our
product and testing service in domestic and international markets will
continue and expand. The Company undertakes no obligation to publicly
update these forward-looking statements to reflect events or
circumstances that occur after the date hereof or to reflect any
change in the Company's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.
Factors that may impact the Company's success are more fully disclosed
in the Company's most recent public filings with the U.S. Securities
and Exchange Commission ("SEC"), including its annual report on Form
10-K/A (No.1) for the year ended December 31, 2001 and its subsequent
filings with the SEC.


CONTACT: Calypte Biomedical Corporation
Nancy Katz, 510/749-5100
nkatz@calypte.com
or
Lippert/Heilshorn & Associates
Brendan Lahiff/Kirsten Chapman, 415/433-3777
brendan@lhai-sf.com

KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY GOVERNMENT MEDICAL
PHARMACEUTICAL MANAGEMENT CHANGES
SOURCE: Calypte Biomedical Corporation

Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: http://www.businesswire.com

Copyright 2003, Business Wire

[streamer]

اخ ممدوح ما هو تاثير الخبر الجديد باعتقادك؟

[الملك الصغير]

في اعتقادي ومثل ما شفت الشارت إن السهم يحترم مستويات الدعم والمقاومة.....وأيضا السهم كان خلال الست شهور الماضية في حالة داون ترند وفي خلال خطين لم يستطع السهم الهروب منها وحتى الآن هو في بين هذين الخطين .....يعني السهم لا زال في داون ترند كبير ....نطاقه في حدود 6 شهور....أعلى سعر للسهم كان قبل ست شهور وهو 0.43.........ارسم خط مستقيم من هذا السعر إلى الارتفاع اللي حققه السهم قبل بومين ......راح إتشوف إن السهم يحترم خط المقاومة هذي:).........إذا السهم فني نوعا ما :)..ولكن إنتظر السهم يعمل بريك آوت للخط هذا:)....وقتها لا تستبعد يوصل السهم ل 0.43:)

الملك الصغير اللي راح يكبر بمساعدتكم:)

[ممدوح]

والله يا اخ streamer ما تعمدت اقرأ الخبر لأنه الآن لا يهمني فقد بعت ما عندي ومستحيل اشتري السهم الآن.
ووجدت الخبرت فقلت ارفقه للمهتمين بالسهم .
على كل سيظهر تاثير الخبر من حركة السهم
اما اذا الخبر زين ولم يتجاوز السهم 8 سنت فأنصح ببيعه
والذي جعلني ابيع السهم هو نزول خبرين حلوين وحركة محدودة جدا في السهم فخفت منه والا المفروض واحد منها يطيره الى 12 سنت على الاقل
على كل اتمنى للجميع التوفيق

[streamer]

الاخوان الملك الصغير وممدوح شكرا لكما ..

واعتقد اخ ممدوح محق فخبرين جيدين ولم يتحرك السهم كما هوا مطلوب منة

علي العموم الله الموفق

[streamer]

باين من تحرك السهم ان ثقة المستثمرين لا زالت غير واضحة المعالم حتي مع ورود 3 اخبار لا باس بهم .. المشكلة الاساسية ترجع ان وضع الشركة غير جيد من ناحية الايرادات والتسويق والكاش !!!

الله الموفق

[السفير]

وينكم يا ممدوح وستريمر والاخوة المهتمين بهذه الشركة
ارتفاع اكثر من 50% خلال هذا الاسبوع مع زيادة واضحة في الفوليوم وايش الرأي
الان سعره
077.

[ممدوح]

بصراحة السهم يستحق المتابعة لتجاوزه اعلى سعر وصله في آخر فترة ارتفاع له
وشوف البلوكات في آخر ساعة
us;CALY Calypte Biomedical Corp # Common Stock
+ 0.0840 Up 0.0220 H 0.0850 L 0.0610 V 11,212,200 31-Jan-03
Price Vol Exc Time ActMMID Price Vol Exc Time ActMMID
0.0713 3000 (U)16.22.15T 0.0820 100 (U)15.55.30
0.0700 500 (U)16.22.03T 0.0810 120 (U)15.55.27
0.0729 6260 (U)16.09.00T 0.0800 115 (U)15.55.18
0.0760 100 (U)16.07.06T 0.0800 100 (U)15.53.24
0.0840 300 (U)16.01.42T 0.0800 100 (U)15.53.15
0.0840 690 (U)16.00.30T 0.0805 75 (U)15.53.03
0.0850 400 (U)16.00.18T 0.0805 90 (U)15.53.03
0.0810 125 (U)16.00.18T 0.0805 210 (U)15.53.03
0.0830 650 (U)16.00.06T 0.0800 500 (U)15.52.33
0.0830 110 (U)16.00.06T 0.0800 100 (U)15.51.42
0.0830 120 (U)16.00.06T 0.0820 100 (U)15.51.42
0.0840 68 (U)15.59.36 0.0810 200 (U)15.51.33
0.0840 90 (U)15.59.18 0.0800 220 (U)15.51.21
0.0830 500 (U)15.58.48 0.0800 100 (U)15.51.15
0.0850 500 (U)15.58.48 0.0810 100 (U)15.51.15
0.0820 300 (U)15.58.48 0.0800 100 (U)15.50.12
0.0830 200 (U)15.57.36 0.0800 92 (U)15.49.36
0.0830 350 (U)15.57.24 0.0800 400 (U)15.49.33
0.0810 1000 (U)15.56.48 0.0800 90 (U)15.49.30
0.0820 1000 (U)15.56.27 0.0790 125 (U)15.48.21
31-Jan-03 16:49 NYC For help: /TT/? (c)REUTERS

[محترف]

الاخوة الافاضل

ماعلمتمون عن سبب الارتفاع و هذة البلكات المطلوبة هل على هذة الشركة اخبار جديدةوالاتو الجماعة

ملتفتين لها بشرون اللة يبشركم بالخير تراها عوايدكم الاخبار الزينة:

[ممدوح]

اليوم نزل خبر على كالي
news (http://biz.yahoo.com/bw/030203/30179_1.html)

[frightful]

الاخ ممدوح مع التحية هل يصلح هذا السهم والدخول فية الان وكم تنصح الخول فية والخروج منة اليوم ولك جزيل الشكر

[سيف الخيال]

نبارك الى اخينا العزيز ممدوح والى جميع الاخوان الاعزاء الذين سنحت لهم الفرصة بالشراء في هذا السهم .

وأتمنى الى الجميع التوفيق ان شاء الله ...

[محترف]

الخبر الى نزل على caly

خبر زين حيث ذكر موافقة الرئس بوش على الحملة التى يتبناها للقضاء على الايدز وكذلك قيام منظمة

الصحة العالمية بالكشف على الايدز با فريقيا امل ان يرفعها ونعوض خسايرنا فى السوق الامريكى
انشاء اللة

[السفير]

ممدوح
الله يجزاك الف خير

[ممدوح]

وخبر جديد
http://biz.yahoo.com/bw/030219/190093_1.html

[streamer]

سوف اعاود الدخول عندما يصل السهم 4 سنت